Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced a collaboration with Biosero, a developer of ...

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...

Barclays analyst Matt Miksic lowered the firm’s price target on Becton Dickinson (BDX) to $278 from $312 and keeps an Overweight rating on the ...

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free ...

"Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company that markets a broad range of devices, laboratory equipment and diagnostic products.

Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals have a strong correlation with market price movements, so we decided to look at ...

Becton, Dickinson and Company is rated a hold due to low growth, valuation concerns, and underperformance compared to healthcare equipment peers. BDX's acquisition of Edwards Lifesciences ...

Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a ...

NYSE:BDX) BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and ...

Shares of Becton Dickinson & Co. BDX shed 1.02% to $237.92 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.61% to 6,086 ...